Somatropin treatment of spinal muscular atrophy: A placebo-controlled, double-blind crossover pilot study-Reference-Cited by-同舟云学术

Somatropin treatment of spinal muscular atrophy: A placebo-controlled, double-blind crossover pilot study

Published:2014-02 Issue:2 Volume:24 Page:134-142
ISSN:0960-8966
Container-title:Neuromuscular Disorders
language:en
Short-container-title:Neuromuscular Disorders

Author:

Kirschner J.,Schorling D.,Hauschke D.,Rensing-Zimmermann C.,Wein U.,Grieben U.,Schottmann G.,Schara U.,Konrad K.,Müller-Felber W.,Thiele S.,Wilichowski E.,Hobbiebrunken E.,Stettner G.M.,Korinthenberg R.

Funder

German Ministry of Education and Research

Publisher

Elsevier BV

Subject

Genetics(clinical),Clinical Neurology,Neurology,Pediatrics, Perinatology, and Child Health

Reference39 articles.

1. Classification of spinal muscular atrophies;Pearn;Lancet,1980

2. Rudnik-Schöneborn S, Wirth B, Grimm T, Zerres K. Spinal muscular atrophies (in german). 2000;60–91.

3. Genetic risk assessment in carrier testing for spinal muscular atrophy;Ogino;Am J Med Genet,2002

4. Identification and characterization of a spinal muscular atrophy-determining gene;Lefebvre;Cell,1995

5. Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype;Campbell;Am J Hum Genet,1997

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic Literature Review of Clinical and Economic Evidence for Spinal Muscular Atrophy;Advances in Therapy;2022-03-20

2. Systematic review of motor function scales and patient reported outcomes in spinal muscular atrophy;American Journal of Physical Medicine & Rehabilitation;2021-09-02

3. Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine;Cell Reports Medicine;2021-07

4. Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment;Frontiers in Pharmacology;2020-11-12

5. Insulin-like growth factor 1 signaling in motor neuron and polyglutamine diseases: From molecular pathogenesis to therapeutic perspectives;Frontiers in Neuroendocrinology;2020-04